Invention Grant
- Patent Title: Azetidine derivatives as CCR-3 receptor antagonist
- Patent Title (中): 氮杂环丁烷衍生物作为CCR-3受体拮抗剂
-
Application No.: US11573232Application Date: 2005-08-09
-
Publication No.: US07691841B2Publication Date: 2010-04-06
- Inventor: Darren M Legrand
- Applicant: Darren M Legrand
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent John Alexander
- Priority: GB0417801.8 20040810
- International Application: PCT/EP2005/008654 WO 20050809
- International Announcement: WO2006/015854 WO 20060216
- Main IPC: A61K31/397
- IPC: A61K31/397 ; A61P29/00 ; A61P37/00 ; C07D205/04 ; C07D277/62 ; C07D401/14 ; C07D403/02 ; C07D413/02

Abstract:
Compounds of formula I in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Public/Granted literature
- US20070259848A1 Azetidine Derivatives as Ccr-e Receptor Public/Granted day:2007-11-08
Information query